Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IIIb study of ravulizumab in Chinese adults with AQP4-positive NMOSD
CTR20262548Phase 3Active
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ravulizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Alexion Pharmaceuticals. Started Aug 2026; status: active.
02
Drugs
ravulizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on CTR20262548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262548.